ArticleAsian Pacific journal of cancer prevention : APJCP2026
Novel Score Based on miRNA-106 b.5p Expression Signature and Routine Biomarkers for Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Patients.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimHepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, particularly among patients with chronic hepatitis C virus (HCV) infection. The limited sensitivity of current diagnostic tools, including imaging and serum alpha-fetoprotein (AFP), underscores the need for novel biomarkers to enable early detection. This study aimed to assess the diagnostic value of circulating miRNA-106 b.5p and to develop an integrated predictive model combining this marker with routine biochemical parameters for early HCC detection in HCV-infected patients.
methodsA total of 42 HCC patients, 83 liver cirrhosis (LC) patients, and 20 healthy controls were enrolled. Serum miRNA-106 b.5p levels were quantified using qRT-PCR, and biochemical markers, including AFP, albumin, platelets, ALT, and bilirubin, were measured. Receiver operating characteristic (ROC) and multivariate discriminant analyses were performed to evaluate diagnostic performance and to construct a combined predictive score.
resultsSerum miRNA-106 b.5p expression was significantly higher in HCC patients compared with LC patients and controls (p < 0.001), showing a progressive increase along the disease spectrum. ROC analysis revealed miRNA-106 b.5p (AUC = 0.679) outperformed AFP (AUC = 0.731) in discriminating HCC from cirrhosis. The newly developed miRNA-106 b.5p HCC score, integrating miRNA-106 b.5p, AFP, albumin, platelet count, total bilirubin, and ALT, achieved 94% sensitivity and 91% specificity (AUC = 0.744) at a cut-off value of 0.42. The model demonstrated superior performance in detecting early-stage and low-grade tumors compared with AFP alone.
conclusionIntegration of miRNA-106 b.5p with routine biochemical markers markedly enhances non-invasive diagnosis of HCV-related HCC. The proposed miRNA-106 b.5p HCC score represents a cost-effective, accurate, and clinically applicable tool for early tumor detection and improved management of high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.